NRX Pharmaceuticals, Inc.

Big Rock Partners Acquisition Corp, listed on Nasdaq under the ticker BRPA, was a blank-check company sponsored by Big Rock Partners that completed its initial public offering in 2017 with a focus on the healthcare and life sciences sector. The vehicle ultimately combined with NRX Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing treatments for severe conditions including treatment-resistant depression and COVID-19. The 10-K/A filed on May 14, 2021 represents an amended annual report for the post-combination entity, reflecting updated disclosures following the de-SPAC transaction. Sign up at SpacDesk for full filing history, sponsor profiles, and deal analytics across the entire SPAC universe.